drugset / Trial / NCT05740475
A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of 9MW3811 in Healthy Subjects
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a first-in-human, single ascending dose study of 9MW3811, the primary objective of which is to evaluate the safety and tolerability of 9MW3811 in healthy adult participants.
Timeline
- Start
- 2023-03-20
- Primary completion
- 2023-09-14
- Completion
- 2024-01-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 9MW3811 | Monoclonal antibody | — | Intravenous |